US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US20040226056A1
(en)
*
|
1998-12-22 |
2004-11-11 |
Myriad Genetics, Incorporated |
Compositions and methods for treating neurological disorders and diseases
|
EP1147214B1
(en)
|
1999-01-13 |
2011-01-05 |
The Research Foundation Of State University Of New York |
A novel method for designing protein kinase inhibitors
|
MXPA02008021A
(es)
*
|
2000-02-15 |
2004-04-05 |
Sugen Inc |
Indolinonas sustituidas con pirroles inhibidoras de proteinquinasas.
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
MY128449A
(en)
|
2000-05-24 |
2007-02-28 |
Sugen Inc |
Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
US6706709B2
(en)
|
2000-06-02 |
2004-03-16 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
US6635640B2
(en)
|
2000-06-30 |
2003-10-21 |
Sugen, Inc. |
4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
|
EP1777218B1
(en)
|
2000-10-20 |
2008-12-31 |
Eisai R&D Management Co., Ltd. |
Process for the preparation of 4-phenoxy quinoline derivatives
|
US6677368B2
(en)
*
|
2000-12-20 |
2004-01-13 |
Sugen, Inc. |
4-aryl substituted indolinones
|
AR042586A1
(es)
*
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
EP1247809A3
(en)
*
|
2001-03-30 |
2003-12-17 |
Pfizer Products Inc. |
Triazine compounds useful as sorbitol dehydrogenase inhibitors
|
AR036042A1
(es)
|
2001-05-30 |
2004-08-04 |
Sugen Inc |
Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
|
US20050176687A1
(en)
*
|
2001-06-29 |
2005-08-11 |
Alain Moussy |
Use of tyrosine kinase inhibitors for treating autoimmune diseases
|
AR038957A1
(es)
*
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
DK1419151T3
(da)
|
2001-08-15 |
2014-03-31 |
Pharmacia & Upjohn Co Llc |
Krystaller indeholdende et malatsyresalt af N-[2-(diethylamino)ethyl]-5-[(5-fluor-1,2-dihydro-2-oxo-3H-indol-3-yliden)methyl]-2,4-dimethyl-1H-pyrrol-3-carboxyamid, fremgangsmåder til fremstilling deraf og sammensætninger deraf
|
JP2005506982A
(ja)
|
2001-09-10 |
2005-03-10 |
スージェン・インコーポレーテッド |
キナーゼ阻害剤としての3−(4,5,6,7−テトラヒドロインドール−2−イルメチリデン)−2−インドリノン誘導体
|
EP1434774A1
(en)
*
|
2001-10-10 |
2004-07-07 |
Sugen, Inc. |
3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
|
US7005445B2
(en)
|
2001-10-22 |
2006-02-28 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors and methods for designing them
|
US7129225B2
(en)
*
|
2001-10-22 |
2006-10-31 |
The Research Foundation Of State University Of New York |
Protection against and treatment of hearing loss
|
US20030080191A1
(en)
*
|
2001-10-26 |
2003-05-01 |
Allen Lubow |
Method and apparatus for applying bar code information to products during production
|
TWI259081B
(en)
*
|
2001-10-26 |
2006-08-01 |
Sugen Inc |
Treatment of acute myeloid leukemia with indolinone compounds
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
AU2002366245A1
(en)
*
|
2001-12-17 |
2003-06-30 |
International Barcode Corporation |
Double-sided bar code doubling as a single bar code
|
US20050131733A1
(en)
*
|
2001-12-17 |
2005-06-16 |
Allen Lubow |
Sealable individual bar coded packets
|
EP1458713B1
(en)
|
2001-12-27 |
2005-08-24 |
Theravance, Inc. |
Indolinone derivatives useful as protein kinase inhibitors
|
JP2005528344A
(ja)
*
|
2002-02-15 |
2005-09-22 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
インドリノン誘導体の製造法
|
WO2003097854A2
(en)
*
|
2002-05-17 |
2003-11-27 |
Sugen, Inc. |
Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
|
ITMI20021620A1
(it)
*
|
2002-07-23 |
2004-01-23 |
Novuspharma Spa |
Composto ad ativita' antitumorale
|
US20060084697A1
(en)
*
|
2002-08-08 |
2006-04-20 |
Hallahan Dennis E |
Pi3k antagonists as radiosensitizers
|
US7195876B2
(en)
*
|
2002-08-09 |
2007-03-27 |
Theravance, Inc. |
Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
|
US20040121407A1
(en)
*
|
2002-09-06 |
2004-06-24 |
Elixir Pharmaceuticals, Inc. |
Regulation of the growth hormone/IGF-1 axis
|
HN2003000272A
(es)
*
|
2002-09-10 |
2008-07-29 |
Pharmacia Italia Spa |
Formulaciones que comprenden un compuesto de indolinona
|
AR042042A1
(es)
*
|
2002-11-15 |
2005-06-08 |
Sugen Inc |
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
|
JP2006510727A
(ja)
*
|
2002-11-15 |
2006-03-30 |
エクセリクシス, インク. |
キナーゼモジュレーター
|
US7452913B2
(en)
*
|
2003-02-24 |
2008-11-18 |
Pharmacia & Upjohn Company |
Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
|
US20040209937A1
(en)
*
|
2003-02-24 |
2004-10-21 |
Sugen, Inc. |
Treatment of excessive osteolysis with indolinone compounds
|
CN103265477B
(zh)
|
2003-02-26 |
2017-01-11 |
苏根公司 |
作为蛋白激酶抑制剂的氨基杂芳基化合物
|
US20040266843A1
(en)
*
|
2003-03-07 |
2004-12-30 |
Sugen, Inc. |
Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
|
US7157577B2
(en)
*
|
2003-03-07 |
2007-01-02 |
Sugen Inc. |
5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
|
JPWO2004080462A1
(ja)
*
|
2003-03-10 |
2006-06-08 |
エーザイ株式会社 |
c−Kitキナーゼ阻害剤
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
DE10334582A1
(de)
*
|
2003-07-28 |
2005-02-24 |
Basf Ag |
Verfahren zur Herstellung von Maleinsäureanhydrid
|
WO2005023765A1
(en)
*
|
2003-09-11 |
2005-03-17 |
Pharmacia & Upjohn Company Llc |
Method for catalyzing amidation reactions by the presence of co2
|
KR20060058728A
(ko)
*
|
2003-10-02 |
2006-05-30 |
파마시아 앤드 업존 캄파니 엘엘씨 |
피롤-치환된 인돌리논 화합물의 염 및 다형체
|
DK1680140T3
(da)
*
|
2003-10-16 |
2011-06-14 |
Imclone Llc |
Fibrolast-vækstfaktorreceptor-1-inhibitorer og fremgangsmåde til behandling deraf
|
WO2005046590A2
(en)
|
2003-11-07 |
2005-05-26 |
Chiron Corporation |
Methods for synthesizing quinolinone compounds
|
JP4303726B2
(ja)
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
JP2007512353A
(ja)
*
|
2003-11-26 |
2007-05-17 |
ザ スクリプス リサーチ インスティテュート |
高機能インドリノン系プロテインキナーゼ阻害剤
|
US20050171182A1
(en)
*
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
US20050152943A1
(en)
*
|
2003-12-23 |
2005-07-14 |
Medtronic Vascular, Inc. |
Medical devices to treat or inhibit restenosis
|
WO2005118543A1
(ja)
*
|
2004-06-03 |
2005-12-15 |
Ono Pharmaceutical Co., Ltd. |
キナーゼ阻害薬およびその用途
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
SE0401790D0
(sv)
*
|
2004-07-07 |
2004-07-07 |
Forskarpatent I Syd Ab |
Tamoxifen response in pre- and postmenopausal breast cancer patients
|
US20060009510A1
(en)
*
|
2004-07-09 |
2006-01-12 |
Pharmacia & Upjohn Company Llc |
Method of synthesizing indolinone compounds
|
ME01788B
(me)
*
|
2004-08-26 |
2011-02-28 |
Pfizer |
Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza
|
KR20070053205A
(ko)
|
2004-09-17 |
2007-05-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
의약 조성물
|
CN100432071C
(zh)
*
|
2004-11-05 |
2008-11-12 |
中国科学院上海药物研究所 |
取代1h-吲哚-2-酮类化合物及其制备方法和用途
|
GT200500321A
(es)
*
|
2004-11-09 |
2006-09-04 |
|
Compuestos y composiciones como inhibidores de proteina kinase.
|
WO2006101692A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
|
NZ562234A
(en)
|
2005-04-26 |
2009-09-25 |
Pfizer |
P-cadherin antibodies
|
KR20070119745A
(ko)
*
|
2005-05-12 |
2007-12-20 |
화이자 인코포레이티드 |
수니티닙 말레이트를 사용하는 항암 병행 요법
|
EP1922307B1
(en)
|
2005-05-18 |
2011-12-28 |
Array Biopharma, Inc. |
Heterocyclic inhibitors of mek and methods of use thereof
|
BRPI0611375A2
(pt)
|
2005-05-23 |
2010-08-31 |
Novartis Ag |
formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
|
BRPI0611419A2
(pt)
*
|
2005-05-26 |
2010-09-08 |
Scripps Research Inst |
composto, sal, tautÈmero ou pró-fármaco, método para a modulação da atividade catalìtica de uma proteìna cinase e processo para a sìntese de uma pirrolil-indolinona
|
US20100105031A1
(en)
*
|
2005-08-01 |
2010-04-29 |
Esai R & D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
RS54393B1
(en)
|
2005-09-07 |
2016-04-28 |
Amgen Fremont Inc. |
HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
|
US20080275101A1
(en)
*
|
2005-09-19 |
2008-11-06 |
Pfizer Inc. |
Solid Salt Forms Of A Pyrrole Substituted 2-Indolinone
|
WO2007052849A1
(ja)
|
2005-11-07 |
2007-05-10 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質とc-kitキナーゼ阻害物質との併用
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
EP1971333A4
(en)
*
|
2005-12-29 |
2009-05-20 |
Scripps Research Inst |
AMINO ACID DERIVATIVES OF PROTEIN KINASE INHIBITORS ON INDOLINONE BASE
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
CN101007801A
(zh)
*
|
2006-01-27 |
2007-08-01 |
上海恒瑞医药有限公司 |
吡咯取代的2-二氢吲哚酮衍生物、其制法与医药上的用途
|
TW200808739A
(en)
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
BRPI0710510A2
(pt)
|
2006-04-19 |
2011-08-16 |
Novartis Ag |
compostos indazol e processos para inibição de cdc7
|
EA200802058A1
(ru)
|
2006-05-09 |
2009-06-30 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и их фармацевтические композиции
|
CN101443009A
(zh)
*
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
DE102006024834B4
(de)
*
|
2006-05-24 |
2010-07-01 |
Schebo Biotech Ag |
Neue Indol-Pyrrol-Derivate und deren Verwendungen
|
WO2008001956A1
(fr)
*
|
2006-06-29 |
2008-01-03 |
Eisai R & D Management Co., Ltd. |
Agent thérapeutique contre la fibrose hépatique
|
US7838542B2
(en)
|
2006-06-29 |
2010-11-23 |
Kinex Pharmaceuticals, Llc |
Bicyclic compositions and methods for modulating a kinase cascade
|
US20080025946A1
(en)
|
2006-07-13 |
2008-01-31 |
Sivakumar Pallavur V |
Interleukin 21 and tyrosine kinase inhibitor combination therapy
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
PE20080538A1
(es)
|
2006-08-04 |
2008-06-18 |
Takeda Pharmaceutical |
Derivado heterociclico fusionado y su uso
|
HUE033894T2
(en)
*
|
2006-08-23 |
2018-01-29 |
Kudos Pharm Ltd |
2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors
|
US8865737B2
(en)
|
2006-08-28 |
2014-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
CA2662902C
(en)
|
2006-09-15 |
2015-11-24 |
Xcovery, Inc. |
Kinase inhibitor compounds
|
MY146474A
(en)
|
2006-11-06 |
2012-08-15 |
Supergen Inc |
Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
|
CN101535302A
(zh)
*
|
2006-11-06 |
2009-09-16 |
株式会社泰丽巴镠斯 |
新型羟基吲哚衍生物
|
ES2383084T3
(es)
|
2006-12-04 |
2012-06-18 |
Jiangsu Simcere Pharmaceutical R&D Co., Ltd. |
Derivados de 3-pirrolo[b]ciclohexilen-2-dihidroindolinona y usos de los mismos
|
KR101445892B1
(ko)
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암 치료용 조성물
|
CA2677365A1
(en)
|
2007-02-06 |
2008-08-14 |
Pfizer Inc. |
2-amino-5, 7-dihydro-6h-pyrrolo [3, 4-d] pyrimidine derivatives as hsp- 90 inhibitors for treating cancer
|
EP2138497A4
(en)
|
2007-03-20 |
2012-01-04 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
US20090004213A1
(en)
*
|
2007-03-26 |
2009-01-01 |
Immatics Biotechnologies Gmbh |
Combination therapy using active immunotherapy
|
US20090042906A1
(en)
*
|
2007-04-26 |
2009-02-12 |
Massachusetts Institute Of Technology |
Methods for treating cancers associated with constitutive egfr signaling
|
WO2008138184A1
(fr)
|
2007-05-14 |
2008-11-20 |
Shanghai Hengrui Pharmaceutical Co.Ltd. |
Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
|
WO2008145398A1
(en)
*
|
2007-06-01 |
2008-12-04 |
Pfizer Italia S.R.L. |
4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors
|
WO2008150015A1
(en)
|
2007-06-05 |
2008-12-11 |
Takeda Pharmaceutical Company Limited |
Heterobicyclic compounds as kinase inhibitors
|
WO2009025358A1
(ja)
|
2007-08-23 |
2009-02-26 |
Takeda Pharmaceutical Company Limited |
複素環化合物およびその用途
|
US20090062368A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sunitinib
|
LT2197878T
(lt)
*
|
2007-09-06 |
2016-09-26 |
Boston Biomedical, Inc. |
Kinazės inhibitorių kompozicijos ir jų panaudojimas vėžio ir kitų su kinazėmis susijusių ligų gydymui
|
PT2201012E
(pt)
|
2007-10-11 |
2014-09-04 |
Astrazeneca Ab |
Derivados de pirrolo[2,3-d]piridina como inibidores da proteína quinase b
|
CN101848895B
(zh)
|
2007-11-09 |
2013-10-23 |
卫材R&D管理有限公司 |
血管新生抑制物质和抗肿瘤性铂络合物的组合使用
|
CA2699306A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
|
US20100256392A1
(en)
*
|
2007-11-21 |
2010-10-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of sunitinib base and processes for preparation thereof
|
EP2229380A1
(en)
*
|
2007-12-12 |
2010-09-22 |
Medichem, S.A. |
Polymorphic forms of a 3-pyrrole substituted 2-indolinone
|
PL2222675T3
(pl)
|
2007-12-19 |
2014-02-28 |
Genentech Inc |
5-anilinoimidazopirydyny i sposoby zastosowania
|
JP2011506560A
(ja)
|
2007-12-20 |
2011-03-03 |
ノバルティス アーゲー |
Pi3キナーゼ阻害剤として用いられるチアゾール誘導体
|
KR20100099185A
(ko)
|
2007-12-21 |
2010-09-10 |
제넨테크, 인크. |
아자인돌리진 및 이용 방법
|
MX2010008187A
(es)
*
|
2008-01-29 |
2010-08-10 |
Eisai R&D Man Co Ltd |
Uso combinado de inhibidor de angiogenesis y taxano.
|
EP2113248A1
(en)
|
2008-04-29 |
2009-11-04 |
Ratiopharm GmbH |
Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
|
WO2009100929A1
(en)
*
|
2008-02-13 |
2009-08-20 |
Ratiopharm Gmbh |
Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
|
EP2090306A1
(en)
|
2008-02-13 |
2009-08-19 |
Ratiopharm GmbH |
Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
CN101255154B
(zh)
*
|
2008-02-18 |
2011-09-07 |
靳广毅 |
一种取代的2-吲哚啉酮衍生物和制备方法及其应用
|
AU2009215377A1
(en)
*
|
2008-02-21 |
2009-08-27 |
Generics [Uk] Limited |
Novel polymorphs and processes for their preparation
|
EP2098521A1
(en)
*
|
2008-03-06 |
2009-09-09 |
Ratiopharm GmbH |
Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
|
ES2391501T3
(es)
*
|
2008-03-31 |
2012-11-27 |
Teva Pharmaceutical Industries Ltd. |
Procedimientos para preparar sunitinib y sales del mismo
|
EP2280960A1
(en)
*
|
2008-04-16 |
2011-02-09 |
Natco Pharma Limited |
Novel polymorphic forms of sunitinib base
|
US8158656B2
(en)
*
|
2008-05-16 |
2012-04-17 |
Shenzhen Chipscreen Biosciences Ltd. |
2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
RU2468022C2
(ru)
*
|
2008-05-23 |
2012-11-27 |
Шанхай Инститьют Оф Фармасьютикал Индастри |
Производные дигидроиндолона
|
US8263547B2
(en)
*
|
2008-05-28 |
2012-09-11 |
Massachusetts Institute Of Technology |
DISC-1 pathway activators in the control of neurogenesis
|
WO2009150523A1
(en)
*
|
2008-06-13 |
2009-12-17 |
Medichem, S.A. |
Process for preparing a 3-pyrrole substituted 2-indolinone malate salt
|
EP2313396A1
(en)
|
2008-06-23 |
2011-04-27 |
Natco Pharma Limited |
Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
|
EP2138167A1
(en)
*
|
2008-06-24 |
2009-12-30 |
ratiopharm GmbH |
Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
WO2009156837A2
(en)
*
|
2008-06-26 |
2009-12-30 |
Medichem, S.A. |
Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
|
DE102008031038A1
(de)
|
2008-06-30 |
2009-12-31 |
Alexander Priv.-Doz. Dr. Dömling |
Sutent zur Anwendung in der Organtransplantation
|
US8124649B2
(en)
*
|
2008-06-30 |
2012-02-28 |
Cylene Pharmaceuticals, Inc. |
Oxindole compounds
|
AU2009269149B2
(en)
|
2008-06-30 |
2016-03-17 |
Mesoblast, Inc. |
Treatment of eye diseases and excessive neovascularization using a combined therapy
|
CN102137842A
(zh)
*
|
2008-07-02 |
2011-07-27 |
基因里克斯(英国)有限公司 |
3-吡咯取代的2-吲哚酮衍生物的制备
|
CN102203085A
(zh)
*
|
2008-07-10 |
2011-09-28 |
基因里克斯(英国)有限公司 |
用于制备苹果酸舒尼替尼晶体形式的新方法
|
WO2010011834A2
(en)
|
2008-07-24 |
2010-01-28 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib and salts thereof and their polymorphs
|
CN102164913A
(zh)
|
2008-07-24 |
2011-08-24 |
麦迪凯姆股份公司 |
一种3-吡咯替代的2-吲哚酮苹果酸盐的结晶体形式
|
US8993615B2
(en)
*
|
2008-08-08 |
2015-03-31 |
The Johns Hopkins University |
Compositions and methods for treatment of neurodegenerative disease
|
BRPI0917891A2
(pt)
*
|
2008-08-25 |
2015-11-24 |
Amplimmune Inc |
antagonistas de pd-1 e métodos de utilização dos mesmos
|
SI2350129T1
(sl)
|
2008-08-25 |
2015-11-30 |
Amplimmune, Inc. |
Sestavki PD-1 antagonistov in postopek njihove uporabe
|
EP2315764A2
(en)
*
|
2008-08-25 |
2011-05-04 |
Generics [UK] Limited |
Crystalline form of sunitinib and processes for its preparation
|
CA2735084A1
(en)
*
|
2008-08-25 |
2010-03-04 |
Generics [Uk] Limited |
Novel polymorphs of sunitinib and processes for their preparation
|
MX2011002498A
(es)
*
|
2008-09-05 |
2011-08-04 |
Imp Innovations Ltd |
Derivados de isatina para uso como agentes de formacion de imagenes in vivo.
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
EP2350056A1
(en)
*
|
2008-10-10 |
2011-08-03 |
Medichem, S.A. |
Process for preparing a 3-pyrrole subsituted 2-indolinone malate salt
|
EP2181991A1
(en)
|
2008-10-28 |
2010-05-05 |
LEK Pharmaceuticals D.D. |
Novel salts of sunitinib
|
EP2186809A1
(en)
*
|
2008-11-13 |
2010-05-19 |
LEK Pharmaceuticals D.D. |
New crystal form of sunitinib malate
|
US20100222371A1
(en)
*
|
2008-11-20 |
2010-09-02 |
Children's Medical Center Corporation |
Prevention of surgical adhesions
|
US8697874B2
(en)
|
2008-12-01 |
2014-04-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
UY32351A
(es)
|
2008-12-22 |
2010-07-30 |
Astrazeneca Ab |
Compuestos de pirimidinil indol para uso como inhibidores de atr
|
WO2010072740A2
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
|
US8329740B2
(en)
|
2009-01-02 |
2012-12-11 |
Hetero Research Foundation |
Polymorphs of sunitinib malate
|
NZ594594A
(en)
|
2009-01-16 |
2013-11-29 |
Exelixis Inc |
Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
|
NZ594177A
(en)
|
2009-02-05 |
2014-02-28 |
Immunogen Inc |
Novel benzodiazepine derivatives
|
CA2748943A1
(en)
|
2009-02-09 |
2010-08-12 |
Supergen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
US9265764B2
(en)
*
|
2009-02-27 |
2016-02-23 |
Massachusetts Institute Of Technology |
Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
CA2755061A1
(en)
|
2009-03-13 |
2010-09-16 |
Cellzome Limited |
Pyrimidine derivatives as mtor inhibitors
|
WO2010108503A1
(en)
|
2009-03-24 |
2010-09-30 |
Life & Brain Gmbh |
Promotion of neuronal integration in neural stem cell grafts
|
US20120040955A1
(en)
|
2009-04-14 |
2012-02-16 |
Richard John Harrison |
Fluoro substituted pyrimidine compounds as jak3 inhibitors
|
WO2010120386A1
(en)
|
2009-04-17 |
2010-10-21 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
EP2255792A1
(en)
|
2009-05-20 |
2010-12-01 |
Ratiopharm GmbH |
Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
|
US8211901B2
(en)
|
2009-05-22 |
2012-07-03 |
Shenzhen Chipscreen Biosciences Ltd. |
Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
EP2264027A1
(en)
|
2009-05-27 |
2010-12-22 |
Ratiopharm GmbH |
Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
CN101906076B
(zh)
|
2009-06-04 |
2013-03-13 |
深圳微芯生物科技有限责任公司 |
作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
WO2011004200A1
(en)
|
2009-07-10 |
2011-01-13 |
Generics [Uk] Limited |
Novel pyrrole derivatives
|
FR2948940B1
(fr)
|
2009-08-04 |
2011-07-22 |
Servier Lab |
Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
WO2011029807A1
(en)
|
2009-09-11 |
2011-03-17 |
Cellzome Limited |
Ortho substituted pyrimidine compounds as jak inhibitors
|
WO2011033472A1
(en)
|
2009-09-16 |
2011-03-24 |
Ranbaxy Laboratories Limited |
Salts of sunitinib
|
AU2010309882B2
(en)
|
2009-10-20 |
2016-01-28 |
Cellzome Limited |
Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
|
US20120271056A1
(en)
|
2009-11-12 |
2012-10-25 |
Ranbaxy Laboratories Limited |
Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
|
US8916716B2
(en)
|
2009-11-19 |
2014-12-23 |
Ranbaxy Laboratories Limited |
Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
|
KR101740171B1
(ko)
|
2009-11-24 |
2017-05-25 |
메디뮨 리미티드 |
B7―h1에 대한 표적화된 결합 물질
|
JP2013512859A
(ja)
|
2009-12-03 |
2013-04-18 |
大日本住友製薬株式会社 |
トール様受容体(tlr)を介して作用するイミダゾキノリン
|
WO2013022801A1
(en)
|
2011-08-05 |
2013-02-14 |
Forsight Vision4, Inc. |
Small molecule delivery with implantable therapeutic device
|
WO2011095802A1
(en)
|
2010-02-02 |
2011-08-11 |
Generics [Uk] Limited |
Hplc method for analyzing sunitinib
|
WO2011100325A2
(en)
*
|
2010-02-09 |
2011-08-18 |
Sicor Inc. |
Polymorphs of sunitinib salts
|
AR080154A1
(es)
|
2010-02-10 |
2012-03-14 |
Immunogen Inc |
Anticuerpos cd20 y su utilizacion
|
EP2539337A1
(en)
|
2010-02-22 |
2013-01-02 |
F. Hoffmann-La Roche AG |
Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
|
WO2011104555A2
(en)
*
|
2010-02-25 |
2011-09-01 |
Generics [Uk] Limited |
Novel process
|
ES2535116T3
(es)
|
2010-03-04 |
2015-05-05 |
Cellzome Limited |
Derivados de urea sustituida con morfolino como inhibidores de mtor
|
CA2792039A1
(en)
|
2010-03-04 |
2011-09-09 |
Ranbaxy Laboratories Limited |
Process for the direct preparation of malic acid salt of sunitinib
|
WO2011110199A1
(en)
|
2010-03-10 |
2011-09-15 |
Synthon B.V. |
A process for amidation of pyrrole carboxylate compounds
|
WO2011114246A1
(en)
|
2010-03-18 |
2011-09-22 |
Ranbaxy Laboratories Limited |
Process for the preparation of malic acid salt of sunitinib
|
WO2011119777A2
(en)
|
2010-03-23 |
2011-09-29 |
The Johns Hopkins University |
Compositions and methods for treatment of neurodegenerative disease
|
WO2011128699A2
(en)
*
|
2010-04-16 |
2011-10-20 |
Generics [Uk] Limited |
Novel process
|
WO2011134831A1
(en)
|
2010-04-30 |
2011-11-03 |
Cellzome Limited |
Pyrazole compounds as jak inhibitors
|
WO2011138565A1
(fr)
|
2010-05-05 |
2011-11-10 |
Biorebus |
Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
|
EP2392324A1
(en)
|
2010-06-01 |
2011-12-07 |
Societe De Coordination De Recherches Therapeutiques |
Rhenium complexes and their pharmaceutical use
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
EP2586443B1
(en)
|
2010-06-25 |
2016-03-16 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
WO2012000970A1
(en)
|
2010-07-01 |
2012-01-05 |
Cellzome Limited |
Triazolopyridines as tyk2 inhibitors
|
MX2013000083A
(es)
|
2010-07-09 |
2013-02-26 |
Genentech Inc |
Anticuerpos de anti-neuropilina y metodos de uso.
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
JP2013534233A
(ja)
|
2010-08-20 |
2013-09-02 |
セルゾーム リミティッド |
選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
|
WO2012027716A1
(en)
|
2010-08-27 |
2012-03-01 |
Collabrx, Inc. |
Method to treat melanoma in braf inhibitor-resistant subjects
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
CN103328465B
(zh)
|
2010-11-01 |
2015-05-27 |
神隆(昆山)生化科技有限公司 |
使用2-甲硅烷氧基-吡咯类制备3-((吡咯-2-基)亚甲基)-2-吡咯酮类的方法
|
WO2012059941A1
(en)
*
|
2010-11-04 |
2012-05-10 |
Ind-Swift Laboratories Limited |
Process for preparation of sunitinib malate and salts thereof
|
AU2011328237A1
(en)
|
2010-11-09 |
2013-05-23 |
Cellzome Limited |
Pyridine compounds and aza analogues thereof as TYK2 inhibitors
|
WO2012068487A1
(en)
|
2010-11-18 |
2012-05-24 |
Synta Pharmaceuticals Corp. |
Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
|
CA2818612C
(en)
|
2010-11-19 |
2020-12-29 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
TWI410425B
(zh)
|
2010-12-03 |
2013-10-01 |
Lilly Co Eli |
唑并[5,4-b]吡啶-5-基化合物
|
WO2012088529A1
(en)
|
2010-12-23 |
2012-06-28 |
Nektar Therapeutics |
Polymer-sunitinib conjugates
|
US10220020B2
(en)
|
2010-12-23 |
2019-03-05 |
Nektar Therapeutics |
Polymer-des-ethyl sunitinib conjugates
|
CA2825605C
(en)
|
2011-01-31 |
2019-05-07 |
Novartis Ag |
Heterocyclic derivatives
|
ES2717657T3
(es)
|
2011-02-15 |
2019-06-24 |
Immunogen Inc |
Métodos para la preparación de conjugados
|
DK2675794T3
(da)
|
2011-02-17 |
2019-05-06 |
Cancer Therapeutics Crc Pty Ltd |
Selektive fak-inhibitorer
|
ES2691673T3
(es)
|
2011-02-17 |
2018-11-28 |
Cancer Therapeutics Crc Pty Limited |
Inhibidores de Fak
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
US8630703B2
(en)
|
2011-03-09 |
2014-01-14 |
Technion Research & Development Foundation Limited |
Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination
|
CN102115469A
(zh)
*
|
2011-03-21 |
2011-07-06 |
浙江大学 |
吲哚啉-2-酮类衍生物的制备和用途
|
EP2694511A1
(en)
|
2011-04-04 |
2014-02-12 |
Cellzome Limited |
Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
|
KR20140027972A
(ko)
*
|
2011-04-08 |
2014-03-07 |
베타 파마, 인크. |
신규 인돌리논 단백질 키나제 억제제
|
WO2012143320A1
(en)
|
2011-04-18 |
2012-10-26 |
Cellzome Limited |
(7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
|
KR101762999B1
(ko)
|
2011-04-18 |
2017-07-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
종양 치료제
|
CN102898402B
(zh)
*
|
2011-04-26 |
2016-01-20 |
北京大学 |
一种苯并异硒唑酮修饰的吡咯甲酸酯取代的吲哚酮类化合物及其应用
|
WO2012166899A2
(en)
|
2011-06-03 |
2012-12-06 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
ES2834093T3
(es)
|
2011-07-21 |
2021-06-16 |
Sumitomo Dainippon Pharma Oncology Inc |
Inhibidores de proteína quinasa heterocíclicos
|
AU2012288892B2
(en)
|
2011-07-28 |
2016-04-21 |
Cellzome Limited |
Heterocyclyl pyrimidine analogues as JAK inhibitors
|
WO2013017479A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
WO2013017480A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
CA2849340A1
(en)
|
2011-09-20 |
2013-03-28 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
|
BR112014006743A8
(pt)
|
2011-09-21 |
2018-01-09 |
Cellzome Ltd |
composto, uso de um composto, e, método para tratar, controlar, retardar ou impedir uma ou mais condições
|
US9242993B2
(en)
|
2011-10-07 |
2016-01-26 |
Cellzome Limited |
Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
|
CN102499917B
(zh)
|
2011-10-25 |
2014-12-17 |
澳门大学 |
吲哚酮类化合物在制备神经保护药物中的应用
|
WO2013061305A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
CN103130774B
(zh)
*
|
2011-11-22 |
2016-06-22 |
齐鲁制药有限公司 |
具有酪氨酸激酶抑制作用的化合物及其制备方法和应用
|
CN103127096B
(zh)
*
|
2011-12-02 |
2015-11-25 |
杨子娇 |
吡咯基取代的吲哚类化合物在治疗青光眼病的应用
|
CN104169272A
(zh)
|
2011-12-23 |
2014-11-26 |
赛尔佐姆有限公司 |
作为激酶抑制剂的嘧啶-2,4-二胺衍生物
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
CN102491932A
(zh)
*
|
2011-12-26 |
2012-06-13 |
天津科技大学 |
一种3-吲哚啉酮类衍生物及其制备方法及其应用
|
ES2709110T3
(es)
|
2012-03-23 |
2019-04-15 |
Laurus Labs Ltd |
Un proceso mejorado para la preparación de sunitinib y sus sales de adición de ácido
|
EP2838538B1
(en)
|
2012-04-20 |
2017-03-15 |
Annji Pharmaceutical Co., Ltd. |
Cyclopropanecarboxylate esters of purine analogues
|
CN102653521B
(zh)
*
|
2012-04-27 |
2014-08-06 |
首都师范大学 |
吲哚-2-酮的哌嗪硫代甲酰肼衍生物及其制备方法和用途
|
PL399027A1
(pl)
|
2012-04-27 |
2013-10-28 |
Instytut Farmaceutyczny |
Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
|
PL2844282T3
(pl)
|
2012-05-04 |
2019-11-29 |
Pfizer |
Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
|
CN104349779A
(zh)
|
2012-05-16 |
2015-02-11 |
诺华股份有限公司 |
Pi-3激酶抑制剂的剂量方案
|
AU2013270684B2
(en)
|
2012-06-08 |
2018-04-19 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
US20160009686A1
(en)
|
2012-08-17 |
2016-01-14 |
Cancer Therapeutics Crc Pty Limited |
Vegfr3 inhibitors
|
EP2887965A1
(en)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Cytotoxic benzodiazepine derivatives
|
SG11201501464TA
(en)
|
2012-08-31 |
2015-03-30 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
WO2014045101A1
(en)
|
2012-09-21 |
2014-03-27 |
Cellzome Gmbh |
Tetrazolo quinoxaline derivatives as tankyrase inhibitors
|
EP2909181B1
(en)
|
2012-10-16 |
2017-08-09 |
Tolero Pharmaceuticals, Inc. |
Pkm2 modulators and methods for their use
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
JPWO2014098176A1
(ja)
|
2012-12-21 |
2017-01-12 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体のアモルファス及びその製造方法
|
EP2961434A2
(en)
|
2013-02-28 |
2016-01-06 |
ImmunoGen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
JP6423804B2
(ja)
|
2013-02-28 |
2018-11-14 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤を含む複合体
|
AU2014243869A1
(en)
*
|
2013-03-13 |
2015-09-24 |
Boston Biomedical, Inc. |
3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
|
CA2905496A1
(en)
|
2013-03-14 |
2014-09-25 |
Forsight Vision4, Inc. |
Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
|
US10202356B2
(en)
|
2013-03-14 |
2019-02-12 |
Tolero Pharmaceuticals, Inc. |
JAK2 and ALK2 inhibitors and methods for their use
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
CN104119321B
(zh)
*
|
2013-04-28 |
2017-09-08 |
齐鲁制药有限公司 |
二氢吲哚酮衍生物的二马来酸盐及其多晶型物
|
RU2658601C2
(ru)
|
2013-05-14 |
2018-06-21 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
FR3008411B1
(fr)
*
|
2013-07-12 |
2015-07-03 |
Servier Lab |
Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
|
US11136625B2
(en)
|
2013-08-28 |
2021-10-05 |
Crown Bioscience, Inc. (Taicang) |
Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
CA2838587A1
(en)
|
2013-10-18 |
2015-04-18 |
Hari Babu Matta |
Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
|
CA2838585A1
(en)
|
2013-10-18 |
2015-04-18 |
Hari Babu Matta |
An ascorbic acid salt of sunitinib
|
SG11201602625YA
(en)
|
2013-11-01 |
2016-05-30 |
Pfizer |
Vectors for expression of prostate-associated antigens
|
ES2899167T3
(es)
|
2013-12-06 |
2022-03-10 |
Novartis Ag |
Régimen posológico para un inhibidor de fosfatidilinositol 3-cinasas selectivo para la isoforma alfa
|
CN104829596B
(zh)
*
|
2014-02-10 |
2017-02-01 |
石家庄以岭药业股份有限公司 |
吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
|
CN103923014A
(zh)
*
|
2014-05-05 |
2014-07-16 |
宁夏宝马药业有限公司 |
环肌酸制备方法
|
WO2016022750A1
(en)
|
2014-08-08 |
2016-02-11 |
Forsight Vision4, Inc. |
Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
|
MX2017001980A
(es)
|
2014-08-28 |
2017-05-04 |
Eisai R&D Man Co Ltd |
Derivado de quinolina muy puro y metodo para su produccion.
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
JP6852848B2
(ja)
|
2015-01-13 |
2021-03-31 |
国立大学法人京都大学 |
筋萎縮性側索硬化症の予防及び/又は治療剤
|
KR20170122734A
(ko)
|
2015-02-25 |
2017-11-06 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 고미 억제 방법
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
MX2017013383A
(es)
|
2015-04-20 |
2017-12-07 |
Tolero Pharmaceuticals Inc |
Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
|
WO2016184793A1
(en)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
|
DK3527574T3
(da)
|
2015-05-18 |
2022-06-27 |
Sumitomo Pharma Oncology Inc |
Alvocidib-prodrugs, der har øget biotilgængelighed
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
WO2016204193A1
(ja)
|
2015-06-16 |
2016-12-22 |
株式会社PRISM Pharma |
抗がん剤
|
CA2993659A1
(en)
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
MA42953A
(fr)
|
2015-09-22 |
2018-08-01 |
Graybug Vision Inc |
Composés et compositions pour le traitement de troubles oculaires
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
CN108472289A
(zh)
|
2015-11-02 |
2018-08-31 |
诺华股份有限公司 |
磷脂酰肌醇3-激酶抑制剂的给药方案
|
JP2018533596A
(ja)
|
2015-11-12 |
2018-11-15 |
グレイバグ ビジョン インコーポレイテッド |
医学療法のための凝集マイクロ粒子
|
CA3011455A1
(en)
|
2016-01-27 |
2017-08-03 |
Sutro Biopharma, Inc. |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
WO2017139417A1
(en)
|
2016-02-08 |
2017-08-17 |
Vitrisa Therapeutics, Inc. |
Compositions with improved intravitreal half-life and uses thereof
|
EP3228630A1
(en)
|
2016-04-07 |
2017-10-11 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
|
CN107459519A
(zh)
|
2016-06-06 |
2017-12-12 |
上海艾力斯医药科技有限公司 |
稠合嘧啶哌啶环衍生物及其制备方法和应用
|
US10870694B2
(en)
|
2016-09-02 |
2020-12-22 |
Dana Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
SG11201903483VA
(en)
|
2016-10-28 |
2019-05-30 |
Icahn School Med Mount Sinai |
Compositions and methods for treating ezh2-mediated cancer
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
US10287253B2
(en)
|
2016-12-05 |
2019-05-14 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
AU2017370694A1
(en)
|
2016-12-08 |
2019-07-25 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating CDK4/6-mediated cancer
|
US10132797B2
(en)
|
2016-12-19 |
2018-11-20 |
Tolero Pharmaceuticals, Inc. |
Profiling peptides and methods for sensitivity profiling
|
CN106916143B
(zh)
*
|
2017-03-14 |
2019-09-27 |
哈尔滨医科大学 |
一种预防和治疗冠心病的药物及其应用
|
JP7217022B2
(ja)
|
2017-03-23 |
2023-02-02 |
グレイバグ ビジョン インコーポレイテッド |
眼障害の治療のための薬物及び組成物
|
MX2019013363A
(es)
|
2017-05-10 |
2020-01-13 |
Graybug Vision Inc |
Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
EP3684814A1
(en)
|
2017-09-18 |
2020-07-29 |
Sutro Biopharma, Inc. |
Anti-folate receptor alpha antibody conjugates and their uses
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
WO2019173516A1
(en)
|
2018-03-06 |
2019-09-12 |
Icahn School Of Medicine At Mount Sinai |
Serine threonine kinase (akt) degradation / disruption compounds and methods of use
|
EP3539536A1
(en)
|
2018-03-15 |
2019-09-18 |
MH10 Spolka z ograniczona odpowiedzialnoscia |
A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
|
WO2020216450A1
(en)
|
2019-04-25 |
2020-10-29 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous sunitinib
|
EP3802519A1
(en)
|
2018-06-04 |
2021-04-14 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
JP2021530554A
(ja)
|
2018-07-26 |
2021-11-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
異常なacvr1発現を伴う疾患を処置するための方法およびそこで使用するためのacvr1阻害剤
|
JP2022500454A
(ja)
|
2018-09-17 |
2022-01-04 |
ストロ バイオファーマ インコーポレーテッド |
抗葉酸受容体抗体コンジュゲートによる併用療法
|
CN113490499A
(zh)
|
2018-12-04 |
2021-10-08 |
大日本住友制药肿瘤公司 |
用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
|
AU2019407426A1
(en)
|
2018-12-21 |
2021-07-22 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
MX2021009371A
(es)
|
2019-02-12 |
2021-09-10 |
Sumitomo Pharma Oncology Inc |
Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos.
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
EA202192575A1
(ru)
|
2019-03-21 |
2022-01-14 |
Онксео |
Соединения dbait в сочетании с ингибиторами киназ для лечения рака
|
EP3941463A1
(en)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
EP3962951A1
(en)
|
2019-05-03 |
2022-03-09 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
US20230022524A1
(en)
|
2019-05-06 |
2023-01-26 |
Icahn School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of hpk1
|
US20220298143A1
(en)
|
2019-08-31 |
2022-09-22 |
Etern Biopharma (Shanghai) Co., Ltd. |
Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof
|
EP4054579A1
(en)
|
2019-11-08 |
2022-09-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
CN111233841A
(zh)
*
|
2020-03-17 |
2020-06-05 |
湖北扬信医药科技有限公司 |
一种舒尼替尼有关物质及其制备方法和用途
|
WO2023278424A1
(en)
*
|
2021-06-28 |
2023-01-05 |
The Regents Of The University Of California |
Methods for treating and ameliorating t cell related diseases
|
CN113717159A
(zh)
*
|
2021-09-16 |
2021-11-30 |
中国药科大学 |
吲哚酮类化合物及其药物组合物、制备方法及用途
|
CA3237696A1
(en)
|
2021-11-08 |
2023-05-11 |
Progentos Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
US20240058465A1
(en)
|
2022-06-30 |
2024-02-22 |
Sutro Biopharma, Inc. |
Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
|
WO2024017372A1
(zh)
*
|
2022-07-22 |
2024-01-25 |
成都百裕制药股份有限公司 |
一种吲哚酮衍生物及其应用
|